


PHARMACEUTICAL 2023

CYTOKINETICS INC Rank 342 of 446









PHARMACEUTICAL 2023

CYTOKINETICS INC Rank 342 of 446



The relative strengths and weaknesses of CYTOKINETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CYTOKINETICS INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 30% points. The greatest weakness of CYTOKINETICS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is -54%, being 97% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	795,186
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	84,617
Liabilities, Non-Current	191,749
Other Assets	139,136
Other Compr. Net Income	-2,721
Other Expenses	51,156
Other Liabilities	846,309
Other Net Income	-13,597
Other Revenues	94,588
Property and Equipment	80,453
Research and Development	240,813
Selling, General and Administrative Expense	177,977

Output Variable	Value in 1000 USD
Assets	1,014,775
Liabilities	1,122,675
Expenses	469,946
Revenues	94,588
Stockholders Equity	-107,900
Net Income	-388,955
Comprehensive Net Income	-390,316
Economic Capital Ratio	-54%

